F. Crouzat

发表

Immunologic Effectiveness of Maraviroc- and Raltegravir-Containing Regimens (R+M+) versus Raltegravir-Based Regimens That Do Not Include Maraviroc (R+M−)

C. Kovacs, T. Antoniou, M. Loutfy, 2012, Journal of the International Association of Physicians in AIDS Care.

Community-associated methicillin-resistant Staphylococcus aureus infections in men who have sex with men: A case series.

C. Kovacs, M. Mulvey, T. Antoniou, 2007, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen

C. Kovacs, M. Loutfy, B. Varriano, 2019, International journal of STD & AIDS.

Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy

B. Yip, R. Hogg, J. Montaner, 2017, BMC Infectious Diseases.

Cohort profile: the Ontario HIV Treatment Network Cohort Study (OCS).

A. Burchell, M. Loutfy, S. Rourke, 2013, International journal of epidemiology.

Risk factors for grade 3-4 liver enzyme elevation in HIV and hepatitis C coinfected patients on combination antiretroviral therapy.

C. Kovacs, T. Antoniou, M. Loutfy, 2007, AIDS patient care and STDs.

Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort

P. Harrigan, B. Yip, R. Hogg, 2016, BMC Infectious Diseases.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Alcohol consumption, substance use, and depression in relation to HIV Pre-Exposure Prophylaxis (PrEP) nonadherence among gay, bisexual, and other men-who-have-sex-with-men

I. Bogoch, J. Rehm, M. Loutfy, 2020, BMC Public Health.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Impact of Baseline NNRTI Resistance in Antiretroviral-naÃ¯ve Patients with HIV in A Large Urban Clinic

C. Kovacs, M. Loutfy, B. Varriano, 2018 .

Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles

C. Kovacs, M. Loutfy, W. Barrie, 2016, HIV clinical trials.

Changes in renal and metabolic indices after switching from tenofovir disoproxil fumarate– to tenofovir alafenamide–containing ART among individuals with HIV in Canada: A retrospective study

C. Kovacs, Meenakshi Gupta, M. Loutfy, 2021, International journal of STD & AIDS.

Recognizing cognitive and psychiatric changes in the post-highly active antiretroviral therapy era.

C. Kovacs, N. Sheehan, J. Baril, 2012, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

Influence of previous experience with and beliefs regarding anal cancer screening on willingness to be screened among men living with HIV

A. Burchell, J. Raboud, S. Walmsley, 2022, BMC Public Health.

CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018

Richard D Moore, Jennifer S. Lee, Jeffrey N. Martin, 2020, Clinical Infectious Diseases.

Immunologic Effectiveness of Maraviroc- and Raltegravir-Containing Regimens (R+M+) versus Raltegravir-Based Regimens That Do Not Include Maraviroc (R+M−)

C. Kovacs, T. Antoniou, M. Loutfy, 2012, Journal of the International Association of Physicians in AIDS Care.